Search the Newsreel

Relay Therapeutics (RLAY) officer has 748 shares sold to satisfy RSU tax

Relay Therapeutics' Chief Corporate Development Officer, Peter Rahmer, sold 748 shares of common stock at $18.61 per share on July 28, 2026. This sale was non-discretionary and executed to cover income tax withholding obligations from the vesting of 3,051 Restricted Stock Units (RSUs). After …

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

Relay Therapeutics, Inc. (Nasdaq: RLAY) will release its second quarter 2026 financial results and corporate highlights after market close on Thursday, August 6, 2026. The company is a clinical-stage precision medicine company focused on developing therapies for cancer and genetic diseases, utilizing its Dynamo® …

Relay Therapeutics, Inc. Revenue Breakdown – NASDAQ:RLAY

Relay Therapeutics, Inc. (NASDAQ:RLAY) generated $15.36 million USD in revenue last year, primarily from its Small Molecule Precision Medicine segment. This marks an increase from $10.01 million USD in the previous year. The United States was the largest contributor to the company's revenue, accounting …

Relay Therapeutics (RLAY) Projected to Post Earnings on Thursday

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

RLAY|Relay Therapeutics Inc|Price:18.430|Chg%:+0.140

This article provides a comprehensive stock analysis of Relay Therapeutics Inc (RLAY), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite average stock market performance, the company shows strong underlying fundamentals and is trading …

Relay Therapeutics Inc (RLAY) Institutional Confidence

Relay Therapeutics Inc (RLAY) has an institutional shareholding score of 10.00, placing it first among 386 companies in the Biotechnology & Medical Research industry. Institutional shareholding proportion increased by 3.47% quarter-over-quarter, reaching 101.48%. The largest institutional shareholder is ETHSX, holding 507.28K shares, representing 0.39% …

Relay Therapeutics Inc (RLAY) Earnings Forecast: Future EPS & Revenue Growth Estimates

Relay Therapeutics Inc (RLAY) has an earnings forecast score of 8.92, ranking 36th in its industry. Analysts have a "Buy" rating for the stock, with an average price target of $14.50. The company's expected revenue for the next quarter is $872.73K, and EPS is …

Relay Therapeutics Inc (RLAY) Cash Flow

This article provides a detailed cash flow statement for Relay Therapeutics Inc (RLAY), covering quarterly and annual data for operating, investing, and financing activities. It presents key financial figures, including net income, operating gains/losses, changes in working capital, capital expenditures, and net cash flows …

Relay Therapeutics Inc (RLAY) Financial Health: Profitability & Balance Sheet Analysis

Relay Therapeutics Inc (RLAY) currently holds a financial score of 7.47, ranking 117th in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue decreased by 60.93% year-over-year, to $3.00 million, while its net profit …

Relay Therapeutics Inc (RLAY) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Relay Therapeutics Inc (RLAY), indicating its current valuation score is 7.02, ranking 275 out of 386 in the Biotechnology & Medical Research industry. The company's current P/E ratio stands at -11.79. Other key valuation metrics like P/B, …

Relay Therapeutics Inc (RLAY) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Relay Therapeutics Inc (RLAY), detailing its current price momentum score, support and resistance levels, and signals from various technical indicators. It also includes an analysis of moving averages and addresses frequently asked questions about technical ratings and …

Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $31

Goldman Sachs has reiterated its Buy rating on Relay Therapeutics (RLAY.US) and increased its price target to $31. This positive outlook suggests the firm sees strong potential for the biotechnology company's performance.

Relay Therapeutics (RLAY) insider plans sale of 30,000 shares after option exercise

Relay Therapeutics insider Sekar Kathiresan plans to sell 30,000 shares of common stock, valued at $594,414.00, on July 21, 2026, following a stock option exercise. The filing, a Form 144, also noted that 66,055 shares were sold on July 20, 2026, for proceeds of …

Relay Therapeutics stock trades around recent lows as cash burn and pipeline data shape the outlook

Relay Therapeutics (RLAY) stock is currently trading near recent lows, reflecting investor focus on the company's substantial cash burn, ongoing operating losses, and the progress of its early-stage precision oncology pipeline. Despite significant net losses in 2023 driven by R&D, the company maintains a …

Relay Therapeutics, Inc. SEC Filing (Jul 20, 2026)

This article reports on Relay Therapeutics, Inc.'s SEC Form 144 filing from July 20, 2026. The filing indicates a proposed sale of 66,055 shares of common stock by an individual through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,293,555.07. The …

Certain Common Stock of Relay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JUL-2026.

Certain common stocks of Relay Therapeutics, Inc. are under a 61-day lock-up agreement, preventing directors and executive officers from selling or transferring these shares between May 20, 2026, and July 20, 2026. This agreement, made with underwriters Jefferies LLC and TD Securities (USA) LLC, …

Canaccord initiates Relay Therapeutics stock with buy rating

Canaccord has initiated coverage on Relay Therapeutics Inc. (NASDAQ:RLAY) with a buy rating and a price target of $29.00, citing its lead asset zovegalisib. The firm believes zovegalisib, targeting mutant PI3Kα, offers improved efficacy and safety for breast cancer and vascular anomalies. This positive …

Blueport Acquisition (BPAC) Stock Price, News & Analysis